Background:: Postvaricella purpura fulminans is a rare disease in children that is probably causedd by an acquired protein S deficiency resulting from antiprotein S antibodies. The epitopee of these antibodies is unknown.
Introduction n
Purpuraa fulminans (PF) is a disorder characterized by a sudden appearance of rapidly progressivee and painful purpura and ecchymosis, which often develop into large areas of skinn necrosis with bulla formation. In some patients skin grafting of the skin lesions or amputationn of the involved extremities is necessary.' Histologic examination of these skin lesionss reveals thrombosis of the dermal capillaries and venules, with a mild perivascular inflammatoryy infiltration.
1 ' PFF may occur in four different clinical settings: in patients with fulminant, often meningococcall sepsis and acquired protein C deficiency 4 ; in healthy neonates with congenitall homozygous protein C or protein S deficiency" 1 : in patients with heterozygous proteinn C or protein S deficiency after an initial high dose of coumarines 7 ; and in usually youngg children after the onset of otherwise benign infectious diseases.
sl " Postinfectiouss PF is a rare disease. Until now. only about 100 case reports have beenn published. Varicella is one of the precipitating infections.' " The pathogenesis of postvaricellaa PF was not understood for a long time. In 1993. however, an 11-year-old boy wass described with severe thromboembolic disease during recovery from varicella. Protein SS was decreased because of the presence of autoantibodies to protein S. M In the following years,, autoimmune protein S deficiency was confirmed to be the predominant underlying mechanismm in children with postvaricella PF. ' ' " Thee aim of this study was to describe the clinical follow-up of a 5-year-old girl withh postvaricella PF and to detect and prospectively follow the concentrations of antiproteinn S antibodies in this patient and in her 3-year old sister with uncomplicated varicella.. This is the first report to study the binding characteristics of the antiprotein S antibodiess using miniprotein S. a recombinant variant of protein S consisting of the first 2422 amino acids of protein S without the sex hormone binding globulin (SHBG)-likc domain.
Is s

Patientt and methods
Patients s
Eightt days after the onset of varicella, a 5-year-old girl was admitted to the hospital becausee of sudden, progressive, painful ecchymotic areas with surrounding erythema on herr right buttock and above her right and left ankles. The results of the physical examinationn were otherwise normal. The ecchymotic areas were initially interpreted as infectiouss and treated with antibiotics. During the next few days, these areas became largerr and gangrenous, with bullae in the center, and the diagnosis of PF was made ( Figure  la) .. Coagulation studies were performed, showing a normal prothrombin time and activatedd partial thromboplastin time. The free protein S antigen plasma level was 0 U/ml (normall range 0.26 -0.61 U/ml) and the total protein S antigen plasma level was 0.21 U/mll (normal range 0.65-1.OH U/ml). Plasma levels of C4b binding protein (C4BP), antithrombinn activity and protein C activity were in the normal range. Factor V R506Q mutationn and factor II G20210A mutation were not present. Levels of prothrombin fragmentt 1 + 2 and thrombin-antithrombin complexes were both elevated, at 3.18 nmol/L (normall range 0.3-1.6 nmol/L) and 32.9 (JLg/L (normal <4.6 (ig/L), respectively. Lupus anticoagulantt was absent. Assay results for anticardiolipin IgM antibodies were negative, whereass results for anticardiolipin IgG antibodies were positive.
Low-molecular-weightt heparin was administered subcutaneously and given until plasmaa levels of protein S returned to the normal adult range. New skin lesions did not appear,, and the present skin lesions did not extend. Skin lesions were treated with silver sulphadiazinee cream. The gangrenous areas healed during a period of 8 weeks, with severe scarringg (Figure lb) .
Thee 3-year-old sister of the patient had varicella infection as well, but without PF. Plasmaa levels of free protein S antigen and total protein S antigen of this sib and both her parentss were in the normal adult range.
Coagulationn assays Sampless for blood coagulation analyses were obtained by venipuncture and collected into plasticc tubes containing trisodium citrate 3.2%. The ratio of anticoagulant to blood used wass 0.1:0.9 (v/v). Plasma for the coagulation assays was stored at -70°C in small aliquots off 500 (xl. Blood samples were collected on day 15, 22, 29, 36, 50, 64, 78, 92, 122 , and 1522 after the onset of varicella. Levels of antiprotein S antibodies were measured on day 15,, 22, 36, 50, and 152.
Levelss of total and free protein S antigen were measured by enzyme-linked immunosorbentt assay (ELISA) (Dako, Glostrup, Denmark). The free protein S fraction wass determined in the supernatant after precipitation of the C4BP-complexed fraction by additionn of one volume 23% polyethylene glycol 8000 (Sigma, St. Louis, MO, USA) to sixx volumes plasma, 30 minutes incubation on melting ice, and centrifugation (12,000 g X 55 min). The level of C4BP was determined by a microlatex photometric immunoassay (LIA-test;; Boehringer Manheim/Diagnostica Stago, Asnieres-sur-Seine, France). Protein C activityy (Berichrom Protein C; Behringwerke, Marburg, Germany) and antithrombin activityy (Coatest; Chromogemix, Molndal, Sweden) were measured by a chromogenic substratee assay. Levels of prothrombin fragment 1 and 2 and thrombin-antithrombin complexess were determined by ELISA (Enzygnost; Behring, Marburg, Germany). Factor VV R506Q mutation and factor II G20210A mutation were demonstrated by polymerase chainn reactions, as described previously.
1920 Anticardiolipin IgM and IgG antibodies were determinedd by ELISA (CLB, Amsterdam, the Netherlands). The presence of lupus anticoagulantt was tested by diluted PT (Innovin; Dade-Behring, Germany) and confirmed withh dilute Russell viper venom time (dRvvt Screen and Confirm; Gradipur, Australia). 4] , 150 mmol/L NaCl) overnight at 4°C. The plate was washed withh TBS, 0.1% (v/v) Tween-20, 3 mmol/L CaCL, and blocked with the same buffer containingg 3% (w/v) bovine serum albumin. All further dilutions were performed in this buffer.. Patient serum, diluted 1:50 to 1:3,200, was added and incubated at 37°C for two hours.. After washing, paranitrophenylphosphate-conjugated goat-antihuman IgM and IgG weree added and incubated at 37°C for 1 hour. The plate was washed and paranitrophenylphosphatee was added. Color development was monitored at an optical densityy of 405 nm. Pooled normal human plasma was used as a control.
Antibodiess against protein S and mini-protein
Inn the patient, free protein S antigen remained undetectable for 7 weeks and slowly reachedd normal levels at 4 months after the onset of varicella. Total protein S antigen levelss increased more quickly than free protein S antigen levels and reached normal levels aboutt 5 weeks after the onset of varicella (Figure 2A) .
Antibodiess against protein S were detected in the first plasma sample from the patient.. The concentrations of these antibodies decreased over the course of months, while att the same time plasma levels of free protein S antigen and total protein S antigen increasedd and reached normal levels. On day 152 after the onset of varicella, when both freee protein S antigen and total protein S antigen were in the normal range, antiprotein S antibodiess were still detectable in a low concentration (25% of the initial level). In the patient'ss sib, antiprotein S antibodies were detectable as well, although plasma free and totall protein S antigen levels were normal. The concentrations of these antibodies were lowerr than the concentrations of the antiprotein S antibodies in the patient (data not shown). .
Inn the first months after the onset of varicella, 62% of the antiprotein S antibodies weree directed against the first 242 amino acids of protein S and 38% against the SHBG domain.. Five months after the onset of varicella, when plasma levels of free protein S and totall protein S had reached normal adult levels, 86% of the antibodies were directed againstt the first 242 amino acids of protein S ( Figure 2B ). Discussion n Thiss case report shows that after varicella, antiprotein S antibodies may develop that in highh concentrations cause severe acquired protein S deficiency, leading to PF. Lowconcentrationss do not alter plasma levels of protein S antigen and do not cause PF, as demonstratedd by the sib of our patient. So far, the cause of the production of antibodies againstt protein S after varicella is unclear. Cross-reactivity with a common antigen also presentt on protein S is a possible explanation. One study showed binding of antiprotein S antibodiess of a patient to a triplet of varicella peptides. 17 However, in another report the antiproteinn S antibodies of the patient did not cross-react with antigen of varicella virus. 14 Antiphospholipidd antibodies, such as anticardiolipin antibodies, were present in our patient,, as in most patients with PF described in previous reports.
14 "' 6 This observation suggestss a more generalized abnormality of the immune response to infection. This abnormall immune response could be genetically determined, as shown by the presence of antiproteinn S antibodies after varicella in sibs without PF.
l7:i Human leucocyte antigen (HLA)) typing of our patient and sib did not reveal any HLA antigens known to be associatedd with autoimmune disease (data not shown).
Proteinn S is a vitamin K -dependent glycoprotein that is synthesized by hepatocytes,, endothelial cells, and platelets. In plasma, protein S exists in two forms: 40% inn an active, free form and 60% in an inactive, reversible complex with C4BP Unlike otherr vitamin K -dependent coagulation factors, protein S contains a carboxy-terminal SHBG-likee domain that represents about half of the molecule. This SHBG-like domain containss the binding site for C4BP
:: To study the epitope of the antiprotein S antibodies developedd after varicella, miniprotein S was used. Miniprotein S is a recombinant variant off protein S that consists of the first 242 amino acids of protein S and thus lacks the SHBG-likee domain." The current study suggests that protein S has at least two epitopes forr binding with antiprotein S antibodies. One epitope is situated on the first 242 amino acidss of protein S; in our experiments, approximately two thirds of the antiprotein S antibodiess were directed against miniprotein S. Another epitope is probably located on the SHBG-likee domain of protein S; one third of the antibodies were not directed against miniproteinn S. Five months after the onset of varicella, almost 90% of the antiprotein S antibodiess were directed against the first 242 amino acids of protein S. At that time, plasmaa levels of free protein S and total protein S of the patient were in the normal range. Thiss might suggest that the antibodies against the first 242 amino acids of protein S are lesss able to decrease the plasma levels of free and total protein S than those against the SHBG-likee domain. However, more studies in other patients with postvaricella protein S deficiencyy are needed before conclusions can be drawn, especially in view of the heterogeneityy of the autoantibody response after varicella.
AA feature of this heterogeneity is the occurrence of various epitopes on protein S forr binding with antiprotein S antibodies. Other features are the diversity of reported types off antibodies and the extent of inhibition of protein S activity. The antibodies may be IgG, IgM,, or both and monoclonal or polyclonal in nature. In most reported patients, the antibodyy did not have a direct inhibitory effect on the activity of protein S. However, one studyy reported inhibition of protein S activity of 42% in a patient with postvaricella proteinn S deficiency. 21 This may suggest the development of antibodies directed to an epitopee situated in the region of protein S involved in activated protein C cofactor activity. Finally,, autoantibodies may develop not only against protein S, but also against platelet surfacee glycoprotein V. resulting in postvaricella thrombocytopenia.-
